Premkumar Reddy - Onconova Therapeutics Founder, Lead Scientific Advisor and Director
| ONTXDelisted Stock | USD 7.93 0.00 0.00% |
Director
Dr. E. Premkumar Reddy, Ph.D., serves as Director of Onconova Therapeutics, Inc., since February 1999. Since March 2010, Dr. Reddy has served as a Professor and Director of the Experimental Cancer Therapeutics Program at Mount Sinai School of Medicine, or Mount Sinai. From 1992 to February 2010, Dr. Reddy served as a Professor and Director of the Fels Institute for Cancer Research of Temple University. He was the founder and coeditor of the international journal of cancer research, Oncogene, published by Nature Publishing Group since 1999.
| Age | 70 |
| Tenure | 25 years |
| Professional Marks | Ph.D |
| Phone | 267 759 3680 |
| Web | https://www.onconova.com |
Onconova Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.3807) % which means that it has lost $0.3807 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.843) %, meaning that it created substantial loss on money invested by shareholders. Onconova Therapeutics' management efficiency ratios could be used to measure how well Onconova Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| David Grange | Tonix Pharmaceuticals Holding | 70 | |
| Kermit Anderson | Adial Pharmaceuticals | 67 | |
| Richard Markham | Vaxart Inc | 65 | |
| James Treco | Tonix Pharmaceuticals Holding | 62 | |
| Paul Aubert | Bio Path Holdings | N/A | |
| Margaret Bell | Tonix Pharmaceuticals Holding | 58 | |
| Trent Davis | VBI Vaccines | 46 | |
| Ari Azhir | Jaguar Animal Health | 69 | |
| Charles Mather | Tonix Pharmaceuticals Holding | 57 | |
| Glenn Chang | Ibio Inc | 69 | |
| Douglas Morris | Bio Path Holdings | 68 | |
| Randal Chase | GeoVax Labs | 67 | |
| Gregory French | Pulmatrix | 53 | |
| Amy Sing | Bio Path Holdings | 57 | |
| Gregory Divis | Jaguar Animal Health | 50 | |
| Patrick Grace | Tonix Pharmaceuticals Holding | 62 | |
| James Hill | Ibio Inc | 71 | |
| Arthur Elliott | Ibio Inc | 81 | |
| Samuel Saks | Tonix Pharmaceuticals Holding | 62 | |
| Alan Timmins | VBI Vaccines | 54 | |
| Bruce Daugherty | Tonix Pharmaceuticals Holding | 56 | |
Management Performance
| Return On Equity | -0.84 | |||
| Return On Asset | -0.38 |
Onconova Therapeutics Leadership Team
Elected by the shareholders, the Onconova Therapeutics' board of directors comprises two types of representatives: Onconova Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Onconova. The board's role is to monitor Onconova Therapeutics' management team and ensure that shareholders' interests are well served. Onconova Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Onconova Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Henry Bienen, Director | ||
| Ramesh Kumar, Co-Founder, CEO and President and Director | ||
| Anne VanLent, Director | ||
| Ajay Bansal, CFO and Secretary | ||
| Premkumar Reddy, Founder, Lead Scientific Advisor and Director | ||
| Jerome Groopman, Director | ||
| James Marino, Independent Director | ||
| Manoj Maniar, Sr. VP of Product Devel. | ||
| Thomas McKearn, President - Research and Development | ||
| Abraham Oler, Vice President Corporate Development and General Counsel | ||
| Michael Hoffman, Chairman of the Board | ||
| Jack Stover, Director | ||
| Mark CPA, CFO COO | ||
| Victor MD, Chief Officer | ||
| Steven Fruchtman, Senior Vice President - Research and Development, Chief Medical Officer | ||
| Mark Guerin, Principal Accounting Officer and VP of Financial Planning and Accounting | ||
| Steven MD, President CEO | ||
| Mark MD, Chief Officer | ||
| Viren Mehta, Director | ||
| Adar Silverstein, Sr Devel |
Onconova Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Onconova Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.84 | |||
| Return On Asset | -0.38 | |||
| Operating Margin | (89.28) % | |||
| Current Valuation | (4.56 M) | |||
| Shares Outstanding | 21 M | |||
| Shares Owned By Insiders | 0.77 % | |||
| Shares Owned By Institutions | 7.95 % | |||
| Number Of Shares Shorted | 20.7 K | |||
| Price To Earning | (0.87) X | |||
| Price To Book | 1.43 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Onconova Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Onconova Therapeutics' short interest history, or implied volatility extrapolated from Onconova Therapeutics options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Other Consideration for investing in Onconova Stock
If you are still planning to invest in Onconova Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Onconova Therapeutics' history and understand the potential risks before investing.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |